These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23307860)

  • 21. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
    Saxena R; Dwivedi A
    Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
    McCubrey JA; Steelman LS; Abrams SL; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM
    Leukemia; 2008 Apr; 22(4):708-22. PubMed ID: 18337766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis: a promising therapeutic target for ovarian cancer.
    Bamias A; Pignata S; Pujade-Lauraine E
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
    Martin L; Schilder R
    J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting angiogenesis in ovarian cancer.
    Schmitt J; Matei D
    Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted trials in ovarian cancer.
    Ledermann JA; Raja FA
    Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rationale for mTOR inhibition in epithelial ovarian cancer.
    Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy in ovarian cancer.
    Lim HJ; Ledger W
    Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
    Gong H; Nie D; Li Z
    Curr Cancer Drug Targets; 2020; 20(11):853-867. PubMed ID: 32807056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the epigenome in ovarian cancer.
    Murphy SK
    Future Oncol; 2012 Feb; 8(2):151-64. PubMed ID: 22335580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New strategies for the treatment of ovarian cancer.
    Robinson E; Fisher N; Stamelos V; Redman C; Richardson A
    Biochem Soc Trans; 2014 Feb; 42(1):125-9. PubMed ID: 24450639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer].
    Matsumura N; Yamaguchi K; Murakami R; Mandai M; Konishi I
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1316-1320. PubMed ID: 27899771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    Galic V; Coleman RL; Herzog TJ
    Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy.
    Bizama C; García P; Espinoza JA; Weber H; Leal P; Nervi B; Roa JC
    Cancer Treat Rev; 2015 Mar; 41(3):222-34. PubMed ID: 25639632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.